title: Management of twin pregnancies consisting of a complete hydatidiform mole and normal fetus.
abstract: OBJECTIVE
  To report the clinical features, management, and outcome of twin pregnancies consisting of a complete hydatidiform mole and a coexisting normal fetus.
  
  
  METHODS
  Between 1966 and 1997, seven women with complete hydatidiform mole and coexisting normal fetus were treated at the John I. Brewer Trophoblastic Disease Center of Northwestern University Medical School. Clinical features, including presenting symptoms, gestational dates, hCG levels, and complications, as well as route of delivery or evacuation, pregnancy outcome, genetic analysis, and need for chemotherapy were assessed.
  
  
  RESULTS
  Four women required uterine evacuation before 20 weeks' gestation because of vaginal bleeding or medical complications, one woman required an emergency hysterotomy because of hemorrhage at 24 weeks, and two women delivered normal, viable infants at 26 and 34 weeks. The pathologic diagnosis of complete hydatidiform mole was confirmed in each case and the chromosome complement was 46,XX in all molar gestations. Four of seven women required chemotherapy for treatment of nonmetastatic gestational trophoblastic tumors, including both women who delivered viable infants and two of the five women whose pregnancies were evacuated before 24 weeks' gestation. All four patients were treated with five to seven cycles of a 5-day methotrexate regimen and achieved complete remission.
  
  
  CONCLUSIONS
  Patients with a twin pregnancy consisting of a complete mole and a normal fetus are at increased risk for hemorrhage and medical complications, as well as the development of persistent gestational trophoblastic tumor.
authors.affiliation: John I. Brewer Trophoblastic Disease Center and the Department of Obstetrics and Gynecology, Northwestern University Medical School, Chicago, Illinois, USA. dfishman@nmh.org
authors.forename: D A
authors.initials: DA
authors.lastname: Fishman
authors.forename: L A
authors.initials: LA
authors.lastname: Padilla
authors.forename: P
authors.initials: P
authors.lastname: Keh
authors.forename: L
authors.initials: L
authors.lastname: Cohen
authors.forename: M
authors.initials: M
authors.lastname: Frederiksen
authors.forename: J R
authors.initials: JR
authors.lastname: Lurain
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D036861:Delivery, Obstetric; D004200:Diseases in Twins; D005260:Female; D005865:Gestational Age; D006801:Humans; D006828:Hydatidiform Mole / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008727:Methotrexate / Q000627:therapeutic use; D011247:Pregnancy; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D014427:Twins; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*
chemical_list: D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate